Shareholder rights firm calls GeneDx Holdings investors to lead WGS securities fraud class action
Securities fraud class actions have become a consistent feature of the broader biotech listing cycle, and GeneDx Holdings Corp. is now among those facing one. The Schall Law Firm, a nation